Subscribe

Glossary

Anti-Jo-1 antibody

The most common antibody in antisynthetase syndrome. About half the people with that illness have it. Finding it points at a particular mix of muscle, joint, and lung involvement.

This is one antibody, found in about half the people with antisynthetase syndrome, and it's the most common of its family. What it changes is mostly how the illness opens and how fast it gets named. It tells you more about which test somebody happened to order first than it does about how things are likely to go from here.

Quick answerAnti-Jo-1 is the most common antibody in antisynthetase syndrome, and one study of 205 people found it in 49.3 percent. A positive result is associated with joint trouble and with a faster diagnosis. One Hungarian study followed 49 people who had this antibody, and every single one of them had muscle inflammation.
A negative result rules out this antibody rather than the illness. About half of people with antisynthetase syndrome have something else instead, and those people wait longer for an answer. One study of 205 people timed it, and without anti-Jo1 the median wait was five months, while with it the median was three. So if your test came back negative and the picture still fits, that's a reason to ask which other antibodies were checked, and your team can say which ones your panel covered.

What this antibody is

Anti-Jo-1 is an antibody that your immune system has made against one of your own enzymes. That's what an autoantibody is, and the name is the whole of the idea. The enzyme it targets helps build proteins inside your cells, and a family of similar antibodies aim at related enzymes.

Together those antibodies are what define antisynthetase syndrome as an illness. Anti-Jo-1 is much the most common of that family, and it's also the one most laboratories test for first. That second fact turns out to count for a good deal more than you would expect it to.

What a positive result predicts

It predicts a mix of problems rather than one organ. One Hungarian study followed 49 people who had tested positive, and it counted what each one of them had. Muscle swelling was there in 100 percent of them, joint swelling reached 88 percent, and lung scarring reached 73 percent. Raynaud's reached 65 percent. Fever reached 43 percent, mechanic's hands reached 33 percent, and trouble swallowing reached 12 percent, so the list covers four organs and a blood vessel problem besides.

A separate study looked at the question from the other direction entirely. It covered 118 people with definite dermatomyositis, of whom 10 turned out to have anti-Jo-1. That group had more mechanic's hands, more joint trouble, and more lung disease than the rest, with fewer skin findings to show for it.

One more finding from a third study belongs beside those. A Chinese study followed 88 people, where arthritis was more frequent in the anti-Jo-1 group than in the anti-PL-7 group, and that held against the anti-EJ group as well. Those came in at P equals 0.004 and P equals 0.002.

The lungs

This is the part that counts for the most, and it holds across the whole syndrome rather than just this antibody. One study followed that side of it closely enough to be worth reading. It followed 103 people with anti-Jo-1 antibodies and lung disease, whose mean age was 49.2 and of whom 70 percent were women. Ten-year survival in that group came in at 68 percent.

Non-specific interstitial pneumonia was the most common imaging picture there, at 52 percent. That picture overlapping with organizing pneumonia came next in the ranking, at 22 percent. Restriction on lung function testing showed in 98 percent of them, which is very nearly everybody who was tested.

One detail about the timing of all this is worth knowing about. In about half of that group, the two diagnoses came within six months of each other. So the lungs aren't usually a late development, and they're often part of how the illness announces itself in the first place.

Common misconceptions.

Myth. A negative anti-Jo-1 test rules out antisynthetase syndrome.

Reality. It rules out one antibody rather than the illness behind it. One study of 205 people found anti-Jo1 in 49.3 percent, so about half had something else, which means anti-PL7, anti-EJ, anti-PL12, or anti-OJ. Those are tested separately and aren't always ordered together, so if the picture fits and your test was negative, ask which others were checked.

Myth. Testing positive means a worse outcome.

Reality. The evidence points the other way, though not strongly. One study of 828 people found survival unchanged by which antibody a person had, and a second study of 28 people found better survival in the anti-Jo-1 group, at a P value of 0.05. A third, of 205 people, found joint trouble protective, and joint trouble is commoner with this antibody.

Myth. It's a muscle antibody, so it means muscle disease.

Reality. It predicts a good deal more than muscle. One Hungarian study followed 49 people who had it, where muscle inflammation was there in 100 percent, joint swelling reached 88 percent, and lung scarring reached 73 percent. A separate study covered 118 people with dermatomyositis, and the 10 who had this antibody had more joint trouble and more lung disease.

Myth. The antibody level is just a yes or no.

Reality. It rises and falls with other measures rather than holding one value. One Hungarian study looked at the anti-Jo-1 level and found it correlated with creatine kinase and with C-reactive protein, both at the start and through the illness. That isn't a reason to watch the number yourself, and it is the reason the number gets rechecked.

Myth. It's found in everybody with muscle inflammation.

Reality. It's uncommon even among people with muscle inflammation. One study covered 460 people with inflammatory muscle disease, and any antisynthetase antibody showed in 51 of them, or 11.1 percent. Anti-Jo-1 is about half of those, and a second study of 118 people with definite dermatomyositis found it in 10, or 8.5 percent.

Related terms.

References.

  1. Tang HS; Tang IYK; Ho RTC et al. Clinical heterogeneity and prognostic factors of anti-synthetase syndrome: a multi-centred retrospective cohort study. Rheumatology (Oxford). 2025;64:212-220. 10.1093/rheumatology/kead671Multicentre retrospective longitudinal cohort of 205 patients meeting Connor's or Solomon's criteria for antisynthetase syndrome
  2. Szabó K; Bodoki L; Nagy-Vincze M et al. Effect of Genetic and Laboratory Findings on Clinical Course of Antisynthetase Syndrome in a Hungarian Cohort. Biomed Res Int. 2018;2018:6416378. 10.1155/2018/6416378Retrospective study of the clinical database of 49 anti-Jo-1 positive antisynthetase patients followed at a single Hungarian centre
  3. Zamora AC; Hoskote SS; Abascal-Bolado B et al. Clinical features and outcomes of interstitial lung disease in anti-Jo-1 positive antisynthetase syndrome. Respir Med. 2016;118:39-45. 10.1016/j.rmed.2016.07.009Fifteen-year cohort of 103 patients identified with anti-Jo-1 positive antisynthetase syndrome and interstitial lung disease
  4. de Andrade VP; De Souza FHC; Behrens Pinto GL et al. The relevance of anti-Jo-1 autoantibodies in patients with definite dermatomyositis. Adv Rheumatol. 2021;61:12. 10.1186/s42358-021-00171-xRetrospective cohort from 2005 to 2020 of 118 adult patients at a tertiary centre diagnosed with definite dermatomyositis
  5. Cavagna L; Trallero-Araguás E; Meloni F et al. Influence of Antisynthetase Antibodies Specificities on Antisynthetase Syndrome Clinical Spectrum Time Course. J Clin Med. 2019;8. 10.3390/jcm8112013Retrospective analysis of 828 patients with antisynthetase syndrome from the American and European Network of Antisynthetase Syndrome collaborative cohort
  6. Noguchi E; Uruha A; Suzuki S et al. Skeletal Muscle Involvement in Antisynthetase Syndrome. JAMA Neurol. 2017;74:992-999. 10.1001/jamaneurol.2017.0934Cohort study collecting muscle biopsy and blood samples from 460 patients with idiopathic inflammatory myositis across regional referral centres in Japan between October 2010 and December 2014
  7. Sreevilasan SK; Devarasetti P; Narahari NK et al. Clinical profile and treatment outcomes in antisynthetase syndrome: a tertiary centre experience. Rheumatol Adv Pract. 2021;5:ii10-ii18. 10.1093/rap/rkab054Prospective follow-up of 28 patients classified as antisynthetase syndrome by Connors criteria at a tertiary centre over 5 years
  8. Wang R; Zhao Y; Qi F et al. Analysis of the clinical features of antisynthetase syndrome: a retrospective cohort study in China. Clin Rheumatol. 2023;42:703-709. 10.1007/s10067-022-06404-8Retrospective cohort of 88 patients diagnosed with antisynthetase syndrome at one Chinese hospital between January 2015 and December 2020
  9. Zhan X; Yan W; Wang Y et al. Clinical features of anti-synthetase syndrome associated interstitial lung disease: a retrospective cohort in China. BMC Pulm Med. 2021;21:57. 10.1186/s12890-021-01399-5Retrospective cohort of 108 consecutive patients with antisynthetase syndrome-associated interstitial lung disease at one Beijing hospital

Free download

The First Changes to Make.

The same handout I hand my own patients: the specific food and daily-exposure changes worth making first, no guesswork required.

We'll email you the list and keep your address so we can send you something occasionally. We won't sell it or pass it on, and you can unsubscribe from any email. How we handle it.

No spam · Unsubscribe any time

This page gathers the published research on this subject into one place. The studies behind it were published between 1989 and 2026, and every figure links to the paper it came from. Those studies were peer reviewed. This summary of them was not. Dr. Sarah Luebker is reviewing these pages one at a time and has not reached this one yet, so it carries no medical review date and nothing here is her opinion or her advice to you. Each page gets updated as she reaches it. It is here in the meantime because the science is worth having in one organized place that is easy to find and easy to read. Talk to your own clinician before acting on any of it.